iECURE, inc.

We’re honored to share that iECURE has been named a finalist for the 2025 Citeline Awards in the Excellence in Rare Disease category! We're proud to be among a group of innovators working to bring hope and transformative treatments to those who need them most. This recognition reflects our team’s commitment to developing meaningful genetic therapies for patients with rare and life-threatening diseases. Thank you, Citeline for this incredible distinction! Learn more: https://lnkd.in/gzMn_3G2 #CitelineAwards #raredisease

On this #WorldHealthDay, we stand alongside the global health community in advocating for Healthy Beginnings, Hopeful Futures, because every mother and newborn deserves the chance to survive and thrive.   This year’s theme is a critical call to action: too many lives are lost to preventable maternal and newborn deaths. At iECURE, we believe that innovation in genetic medicine can play a role in shaping a healthier future, one where advancements in science help address unmet medical needs and improve outcomes for families worldwide.   We remain committed to pushing the boundaries of #GeneticMedicine, driven by the hope that every child has the opportunity for a healthier tomorrow. Learn how we are taking action with our OTC-HOPE study: http://bit.ly/4hUF6x7   #HealthyBeginnings #HopefulFutures #HealthForAll

We’re honored to support the National Urea Cycle Disorders Foundation in advancing awareness, research, and care for those affected by UCDs. Please join us in following NUCDF as they share important info on UCD and raise awareness throughout April. #TogetherForACure

At iECURE, we’re pushing the boundaries of #geneticmedicine to transform lives. Our mission-driven team is growing, and we’re looking for passionate individuals to help us advance cutting-edge therapies for patients in need.   If you’re looking to make a real impact in biotech, join our team. Learn more about our open roles and apply today: https://lnkd.in/ebQNNRJb   #Hiring #BiotechJobs

We are pleased to share data presented today at the 2025 ACMG - American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting from the ongoing OTC-HOPE Phase 1/2 #ClinicalTrial of our in vivo gene editing candidate. The data builds upon previously announced preliminary findings from the first infant dosed in the OTC-HOPE study and suggests partial restoration of functional ornithine transcarbamylase (#OTC) enzyme activity in the liver.     Read the full press release: https://lnkd.in/gT8Fdziv

Thanks to Life Sciences Pennsylvania for hosting the 2025 Annual Dinner & Showcase at the Philadelphia Museum of Art. It was a fantastic evening of networking and celebrating the achievements of Pennsylvania's life sciences community. Congratulations to all the award nominees and winners! #LifeSciencesPA #Biotech #Innovation

We look forward to sharing initial data from the Phase 1/2 OTC-HOPE clinical trial evaluating our in vivo gene editing candidate, ECUR-506, in neonatal onset ornithine transcarbamylase (OTC) deficiency at the 2025 ACMG - American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting this month.    The presentation will follow up from the data reported earlier this year, highlighting a complete clinical response, as per study protocol, in the first infant dosed in the ongoing OTC-HOPE study. Be sure to stop by Booth #441 to connect with the iECURE team onsite. Learn more: https://lnkd.in/gJEmFbte    #ACMGMtg25 

To our entire team at iECURE and everyone who contributes to our work: your dedication, innovation, and passion fuel our mission to bring life-changing #geneticmedicines to patients in need. Today, we pause to say thank you for being the heart of iECURE and for pushing the boundaries of what’s possible! Learn more about career opportunities at iECURE here: https://lnkd.in/ebQNNRJb   #EmployeeAppreciationDay

We’re thrilled to share that the second site in Spain for the OTC-HOPE #ClinicalTrial is now open and enrolling patients! Hospital Universitario 12 de Octubre in Madrid, Spain, has officially joined this promising study, led by Principal Investigator, Dr. marcello bellusci.   Learn more about the trial and eligibility criteria here: https://bit.ly/3F4Dfbk    #SiteOpen #OTCdeficiency

We look forward to connecting with the investment community at the Leerink Partners Global Healthcare Conference in Miami next week to share our latest advancements in #geneticmedicine. Reach out to your Leerink Partners representative to meet 1x1 with members of our team on Monday, March 10. #biotech #rarediseases